J 2019

Prognostic Accuracy of Three COPD Classification Systems in Relation to Long-Term Mortality of COPD Patients: A Prospective Multicenter Study

PLUTINSKÝ, Marek; Kristián BRAT; Michal SVOBODA; Jaromir ZATLOUKAL; Patricie POPELKOVA et al.

Základní údaje

Originální název

Prognostic Accuracy of Three COPD Classification Systems in Relation to Long-Term Mortality of COPD Patients: A Prospective Multicenter Study

Autoři

PLUTINSKÝ, Marek; Kristián BRAT; Michal SVOBODA; Jaromir ZATLOUKAL; Patricie POPELKOVA a Vladimir KOBLIZEK

Vydání

LUNG, NEW YORK, SPRINGER, 2019, 0341-2040

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 1.817

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/19:00109670

Organizační jednotka

Lékařská fakulta

EID Scopus

Klíčová slova anglicky

COPD; GOLD classification; Prognosis; Mortality

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 16. 5. 2019 14:44, Soňa Böhmová

Anotace

V originále

Recent research showed group B patients express higher mortality compared to group C patients when GOLD A-D grouping is used. We aimed to compare the prognostic accuracy of three GOLD classification systems, I-IV (pre-2011), A-D (2011-2016) and A-D (2017-present) in relation to mortality, exacerbation risk, quality of life (QoL) assessment and specific treatments use in a real-life COPD cohort. We used the data of 720 patients from the Czech Multicenter Research Database of COPD. Four-year mortality and time-to-exacerbation using the GOLD pre-2011, 2011-2016 and 2017-present classification schemes were assessed. Moreover, distribution of specific treatments use and QoL measures were analyzed. The GOLD I-IV classification system showed gradual increase in 4-year mortality across the stages (GOLD II 18.8%, III 28.5%, IV 38.7%) (p=0.001). Using the A-D 2011-2016 classification scheme, group C patients had lower mortality (16.7%) than group B (18.7%) (p=0.009). The A-D 2017-present classification showed higher mortality in group B (25.5%) compared to group C (20%) (p=0.05). For additional outcomes, the GOLD I-IV scheme showed highest match between the calculated 4-year exacerbation risk and QoL measures and GOLD stage/grouping. In terms of specific treatment distributions, various patterns for each GOLD classification system were observed with best match of GOLD 2017-present system to the layout of GOLD groups and categories. We conclude the GOLD I-IV classification system had the highest accuracy related to mortality, QoL measures and exacerbation risk prediction, while the A-D 2017-present scheme was most accurate within severity of symptoms prediction reflected also by more frequent specific treatments use.